From covalent transition states in chemistry to noncovalent in biology: from β- to Φ-value analysis of protein folding
AR Fersht
Q Rev Biophys
(2024)
57
NF-κB Rel subunit exchange on a physiological timescale
M Biancalana, E Natan, MJ Lenardo, AR Fersht
Protein Sci
(2021)
30
AlphaFold - A Personal Perspective on the Impact of Machine Learning
AR Fersht
J Mol Biol
(2021)
433
Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm
MR Bauer, A Krämer, G Settanni, RN Jones, X Ni, R Khan Tareque, AR Fersht, J Spencer, AC Joerger
ACS Chemical Biology
(2020)
15
ChemBioChem@20-Some Reflections
AR Fersht, P Gölitz, J-M Lehn
Chembiochem
(2019)
21
A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C
MR Bauer, RN Jones, RK Tareque, B Springett, FA Dingler, L Verduci, KJ Patel, AR Fersht, AC Joerger, J Spencer
Future Med Chem
(2019)
11
SLMP53-2 restoreswild-type-like function to mutant p53 through hsp70: Promising activity in hepatocellular carcinoma
S Gomes, B Bosco, JB Loureiro, H Ramos, L Raimundo, J Soares, N Nazareth, V Barcherini, L Domingues, C Oliveira, A Bisio, S Piazza, MR Bauer, JP Brás, MI Almeida, C Gomes, F Reis, AR Fersht, A Inga, MMM Santos, L Saraiva
Cancers
(2019)
11
Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines.
MGJ Baud, MR Bauer, L Verduci, FA Dingler, KJ Patel, D Horil Roy, AC Joerger, AR Fersht
European Journal of Medicinal Chemistry
(2018)
152
The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53.
E Madan, TM Parker, MR Bauer, A Dhiman, CJ Pelham, M Nagane, ML Kuppusamy, M Holmes, TR Holmes, K Shaik, K Shee, S Kiparoidze, SD Smith, Y-SA Park, JJ Gomm, LJ Jones, AR Tomás, AC Cunha, K Selvendiran, LA Hansen, AR Fersht, K Hideg, R Gogna, P Kuppusamy
Journal of Biological Chemistry
(2018)
293
Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.
NC Synnott, MR Bauer, S Madden, A Murray, R Klinger, N O'Donovan, D O'Connor, WM Gallagher, J Crown, AR Fersht, MJ Duffy
Cancer letters
(2017)
414
Targeting mutant p53 with PK11007: A new approach for the treatment of patients with triple-negative breast cancer?
NC Synnott, MR Bauer, SF Madden, AM Murray, R Klinger, N O'Donovan, D O'Connor, WM Gallagher, J Crown, AR Fersht, MJ Duffy
Journal of Clinical Oncology
(2017)
35
Structures of closed and open conformations of dimeric human ATM
D Baretić, HK Pollard, DI Fisher, CM Johnson, B Santhanam, CM Truman, T Kouba, AR Fersht, C Phillips, RL Williams
Science advances
(2017)
3
Multisite aggregation of p53 and implications for drug rescue
GZ Wang, AR Fersht
Proceedings of the National Academy of Sciences of the United States of America
(2017)
114
Design of a molecular support for cryo-EM structure determination
TG Martin, TAM Bharat, AC Joerger, X-C Bai, F Praetorius, AR Fersht, H Dietz, SHW Scheres
Proceedings of the National Academy of Sciences
(2016)
113
2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells.
MR Bauer, AC Joerger, AR Fersht
Proceedings of the National Academy of Sciences of the United States of America
(2016)
113
Anin silicoalgorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein
D Bromley, MR Bauer, AR Fersht, V Daggett
Protein engineering, design & selection : PEDS
(2016)
29
Harnessing Fluorine-Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs
MR Bauer, RN Jones, MGJ Baud, R Wilcken, FM Boeckler, AR Fersht, AC Joerger, J Spencer
ACS chemical biology
(2016)
11
The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches.
AC Joerger, AR Fersht
Annual Review of Biochemistry
(2016)
85
Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53
AC Joerger, MR Bauer, R Wilcken, MGJ Baud, H Harbrecht, TE Exner, FM Boeckler, J Spencer, AR Fersht
Structure
(2015)
23
Experimental and Theoretical Evaluation of the Ethynyl Moiety as a Halogen Bioisostere
R Wilcken, MO Zimmermann, MR Bauer, TJ Rutherford, AR Fersht, AC Joerger, FM Boeckler
ACS Chemical Biology
(2015)
10